264 related articles for article (PubMed ID: 29074605)
1. Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms.
Lee J; Minden MD; Chen WC; Streck E; Chen B; Kang H; Arruda A; Ly D; Der SD; Kang S; Achita P; D'Souza C; Li Y; Childs RW; Dick JE; Zhang L
Clin Cancer Res; 2018 Jan; 24(2):370-382. PubMed ID: 29074605
[No Abstract] [Full Text] [Related]
2. Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy.
Chen B; Lee JB; Kang H; Minden MD; Zhang L
J Exp Clin Cancer Res; 2018 Apr; 37(1):88. PubMed ID: 29690909
[TBL] [Abstract][Full Text] [Related]
3. Developing Allogeneic Double-Negative T Cells as a Novel Off-the-Shelf Adoptive Cellular Therapy for Cancer.
Lee JB; Kang H; Fang L; D'Souza C; Adeyi O; Zhang L
Clin Cancer Res; 2019 Apr; 25(7):2241-2253. PubMed ID: 30617140
[TBL] [Abstract][Full Text] [Related]
4. Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15.
Yao J; Ly D; Dervovic D; Fang L; Lee JB; Kang H; Wang YH; Pham NA; Pan H; Tsao MS; Zhang L
J Immunother Cancer; 2019 Jan; 7(1):17. PubMed ID: 30670085
[TBL] [Abstract][Full Text] [Related]
5. Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells.
Fang KK; Lee J; Khatri I; Na Y; Zhang L
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37678917
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
[TBL] [Abstract][Full Text] [Related]
7. The CD226-ERK1/2-LAMP1 pathway is an important mechanism for Vγ9Vδ2 T cell cytotoxicity against chemotherapy-resistant acute myeloid leukemia blasts and leukemia stem cells.
Wu K; Wang LM; Liu M; Xiu Y; Hu Y; Fu S; Huang H; Xu B; Xiao H
Cancer Sci; 2021 Aug; 112(8):3233-3242. PubMed ID: 34107135
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive analysis of primary acute myeloid leukemia identifies biomarkers predicting susceptibility to human allogeneic Vγ9Vδ2 T cells.
Gundermann S; Klinker E; Kimmel B; Flierl U; Wilhelm M; Einsele H; Kunzmann V
J Immunother; 2014; 37(6):321-30. PubMed ID: 24911793
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.
Sheng L; Mu Q; Wu X; Yang S; Zhu H; Wang J; Lai Y; Wu H; Sun Y; Hu Y; Fu H; Wang Y; Xu K; Sun Y; Zhang Y; Zhang P; Zhou M; Lai B; Xu Z; Gao M; Zhang Y; Ouyang G
Front Immunol; 2020; 11():1534. PubMed ID: 32849519
[No Abstract] [Full Text] [Related]
10. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
11. HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.
Herr W; Eichinger Y; Beshay J; Bloetz A; Vatter S; Mirbeth C; Distler E; Hartwig UF; Thomas S
Leukemia; 2017 Feb; 31(2):434-445. PubMed ID: 27479183
[TBL] [Abstract][Full Text] [Related]
12. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
13. NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML.
Schlegel P; Ditthard K; Lang P; Mezger M; Michaelis S; Handgretinger R; Pfeiffer M
J Immunol Res; 2015; 2015():473175. PubMed ID: 26236752
[TBL] [Abstract][Full Text] [Related]
14. Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy.
Merims S; Li X; Joe B; Dokouhaki P; Han M; Childs RW; Wang ZY; Gupta V; Minden MD; Zhang L
Leukemia; 2011 Sep; 25(9):1415-22. PubMed ID: 21566657
[TBL] [Abstract][Full Text] [Related]
15. TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells.
Nieda M; Nicol A; Koezuka Y; Kikuchi A; Lapteva N; Tanaka Y; Tokunaga K; Suzuki K; Kayagaki N; Yagita H; Hirai H; Juji T
Blood; 2001 Apr; 97(7):2067-74. PubMed ID: 11264173
[TBL] [Abstract][Full Text] [Related]
16. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
17. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.
Zhang M; Sukhumalchandra P; Enyenihi AA; St John LS; Hunsucker SA; Mittendorf EA; Sergeeva A; Ruisaard K; Al-Atrache Z; Ropp PA; Jakher H; Rodriguez-Cruz T; Lizee G; Clise-Dwyer K; Lu S; Molldrem JJ; Glish GL; Armistead PM; Alatrash G
Clin Cancer Res; 2013 Jan; 19(1):247-57. PubMed ID: 23147993
[TBL] [Abstract][Full Text] [Related]
18. Double-negative T cells utilize a TNFα-JAK1-ICAM-1 cytotoxic axis against acute myeloid leukemia.
Tin E; Lee J; Khatri I; Na Y; Minden MD; Zhang L
Blood Adv; 2024 Mar; ():. PubMed ID: 38547431
[TBL] [Abstract][Full Text] [Related]
19. Decitabine enhances targeting of AML cells by CD34
Cany J; Roeven MWH; Hoogstad-van Evert JS; Hobo W; Maas F; Franco Fernandez R; Blijlevens NMA; van der Velden WJ; Huls G; Jansen JH; Schaap NPM; Dolstra H
Blood; 2018 Jan; 131(2):202-214. PubMed ID: 29138222
[TBL] [Abstract][Full Text] [Related]
20. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
